Early detection is crucial in the battle against breast cancer. This systematic review explores the potential of artificial intelligence (AI) in predicting future breast cancer risk using mammograms. We analyze existing studies to evaluate the accuracy, reliability, and clinical implications of AI-driven risk assessment models. By understanding the strengths and limitations of these models, we aim to inform future research and clinical practice.
Breast cancer remains a significant public health concern worldwide. Early detection through regular mammograms has been instrumental in reducing mortality rates. However, mammograms have limitations in predicting future cancer risk. Recent advancements in artificial intelligence (AI) offer promising opportunities to improve breast cancer risk assessment. This review delves into the current state of AI-driven mammography-based breast cancer risk prediction models.
Artificial intelligence has made remarkable strides in various fields, including healthcare. In radiology, AI algorithms have demonstrated exceptional performance in detecting abnormalities in medical images. Specifically, AI-powered mammogram analysis has shown promise in identifying subtle signs of breast cancer that might be missed by human radiologists.
Beyond detecting existing cancers, AI has the potential to predict the likelihood of developing breast cancer in the future. By analyzing mammographic images, AI algorithms can identify subtle patterns and features associated with increased risk. These models could be used to prioritize screening, target preventive interventions, and ultimately reduce breast cancer mortality.
To conduct this review, we systematically searched relevant databases for studies investigating AI-driven mammography-based breast cancer risk prediction. Inclusion and exclusion criteria were defined to ensure the quality and relevance of included studies. The extracted data included study design, sample size, AI algorithm, performance metrics, and clinical implications.
The included studies demonstrated varying levels of accuracy in predicting breast cancer risk using AI-driven mammogram analysis. Several factors influenced model performance, including the type of AI algorithm, dataset size, and image quality. While some studies reported promising results, further research is needed to validate these findings in larger and more diverse populations.
The integration of AI-driven breast cancer risk prediction models into clinical practice could revolutionize preventive care. By identifying women at higher risk, healthcare providers can offer tailored screening and prevention strategies. However, challenges such as model interpretability, ethical considerations, and patient acceptance must be addressed.
AI-driven mammography-based breast cancer risk prediction holds significant promise for improving early detection and prevention. While the field is still in its early stages, the potential benefits are substantial. Continued research and development are essential to refine these models and translate them into clinical practice. By harnessing the power of AI, we can move closer to a future where breast cancer is a preventable disease.
1.
Retired Olympic athletes at greater risk of skin cancer and osteoarthritis, research reveals
2.
Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer
3.
Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT
4.
Year in Review: Non-Small Cell Lung Cancer
5.
Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries
1.
What Is Carboxyhemoglobin And How Can It Affect Your Health?
2.
Introducing the Corrected Calcium Calculator: A Revolutionary Tool in Medical Assessment
3.
Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment
4.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
5.
The Importance of Having a Quick and Effective Heparin Antidote
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
2.
Navigating the Complexities of Ph Negative ALL - Part XVI
3.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation